Beauty Health (SKIN) Financials

Beauty Health logo
$12.46 -1.42 (-10.23%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$12.44 -0.02 (-0.12%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Beauty Health

Annual Income Statements for Beauty Health

This table shows Beauty Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-1.64 -29 -379 44 -100 -29 -9.52
Consolidated Net Income / (Loss)
-1.64 -29 -379 44 -100 -29 -9.52
Net Income / (Loss) Continuing Operations
-1.64 -29 -379 44 -100 -29 -9.52
Total Pre-Tax Income
-2.94 -38 -381 45 -102 -30 -5.94
Total Operating Income
13 -17 -40 -26 -131 -68 -21
Total Gross Profit
107 67 179 249 155 182 196
Total Revenue
167 119 260 366 398 334 301
Operating Revenue
- 119 260 366 398 334 301
Total Cost of Revenue
60 52 82 117 243 152 104
Operating Cost of Revenue
60 52 82 117 243 152 104
Total Operating Expenses
93 84 218 275 286 250 217
Selling, General & Admin Expense
27 31 99 106 131 125 118
Marketing Expense
62 50 112 160 144 118 94
Research & Development Expense
4.61 3.41 8.20 8.44 10 6.30 5.63
Total Other Income / (Expense), net
-16 -21 -341 71 29 38 15
Interest Expense
- - 12 13 14 10 19
Interest & Investment Income
-17 -21 0.04 9.18 23 17 8.95
Other Income / (Expense), net
0.70 -0.03 -329 75 20 32 25
Income Tax Expense
-1.30 -9.31 -1.88 1.12 -1.77 -0.45 3.58
Basic Earnings per Share
($0.05) ($0.85) ($3.71) $0.30 ($0.76) ($0.23) ($0.08)
Weighted Average Basic Shares Outstanding
32.14M 34.29M 102.11M 147.55M 131.68M 123.83M 126.38M
Diluted Earnings per Share
($0.05) ($0.85) ($3.71) ($0.23) ($0.76) ($0.36) ($0.16)
Weighted Average Diluted Shares Outstanding
32.14M 34.29M 102.11M 148.51M 131.68M 142.49M 135.80M
Weighted Average Basic & Diluted Shares Outstanding
- 11.78M 150.60M 132.50M 123.43M 125.25M 127.77M

Quarterly Income Statements for Beauty Health

This table shows Beauty Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63 -2.67 -0.89
Consolidated Net Income / (Loss)
-0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63 -2.67 -0.89
Net Income / (Loss) Continuing Operations
-0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63 -2.67 -0.89
Total Pre-Tax Income
-1.34 -0.15 -16 -12 -9.20 19 -11 -4.81 -6.81 -1.46 -0.11
Total Operating Income
-17 -22 -22 -7.16 -12 -2.70 -6.24 0.16 -1.80 3.57 4.98
Total Gross Profit
48 41 41 52 49 49 46 53 44 49 47
Total Revenue
81 91 79 83 70 78 71 82 65 72 69
Operating Revenue
81 91 79 83 70 78 71 82 65 72 69
Total Cost of Revenue
33 50 38 31 21 29 25 29 20 23 22
Operating Cost of Revenue
33 50 38 31 21 29 25 29 20 23 22
Total Operating Expenses
65 63 62 60 61 52 52 53 46 46 42
Selling, General & Admin Expense
29 31 33 32 34 27 29 28 22 23 20
Marketing Expense
34 30 28 27 26 23 21 24 23 21 20
Research & Development Expense
2.81 1.16 1.11 1.22 1.00 1.25 1.70 1.68 1.10 1.41 1.66
Total Other Income / (Expense), net
16 22 5.17 -4.56 2.82 21 -4.40 -4.97 -5.01 -5.03 -5.09
Interest Expense
3.03 2.45 2.47 2.46 2.50 4.14 6.31 6.37 6.35 6.30 6.27
Interest & Investment Income
5.36 4.19 4.88 2.22 3.03 3.16 1.26 1.51 1.49 1.29 1.39
Other Income / (Expense), net
13 20 2.76 -4.32 2.29 22 0.65 -0.11 -0.15 -0.03 -0.21
Income Tax Expense
-0.66 -0.35 1.95 -1.39 0.89 -0.99 0.39 3.30 -0.18 1.21 0.78
Basic Earnings per Share
($0.01) $0.00 ($0.15) ($0.07) ($0.08) $0.16 ($1.74) ($0.07) ($0.05) ($0.02) ($0.14)
Weighted Average Basic Shares Outstanding
123.12M 123.72M 124.06M 123.83M 125.08M 126.07M 6.35M 126.38M 127.79M 129.60M 6.51M
Diluted Earnings per Share
($0.10) ($0.10) ($0.15) ($0.01) ($0.08) $0.03 ($1.74) ($0.02) ($0.05) ($0.02) ($0.14)
Weighted Average Diluted Shares Outstanding
144.48M 141.93M 124.06M 142.49M 125.08M 140.29M 6.35M 135.80M 131.40M 129.60M 6.51M
Weighted Average Basic & Diluted Shares Outstanding
123.63M 124.02M 124.12M 125.25M 125.99M 126.83M 127.50M 127.77M 129.60M 130.14M 6.54M

Annual Cash Flow Statements for Beauty Health

This table details how cash moves in and out of Beauty Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
3.83 2.02 893 -331 -47 -149 -143
Net Cash From Operating Activities
1.73 -12 -28 -107 22 16 37
Net Cash From Continuing Operating Activities
1.73 -12 -28 -107 22 16 37
Net Income / (Loss) Continuing Operations
-1.64 -29 -379 44 -100 -29 -9.52
Consolidated Net Income / (Loss)
-1.64 -29 -379 44 -100 -29 -9.52
Depreciation Expense
1.38 2.55 4.49 7.16 11 9.94 3.85
Amortization Expense
14 13 18 20 28 27 25
Non-Cash Adjustments To Reconcile Net Income
0.76 7.65 339 -43 54 23 5.53
Changes in Operating Assets and Liabilities, net
-13 -6.92 -10 -135 29 -15 12
Net Cash From Investing Activities
-12 -3.82 -38 -19 -32 -6.79 -5.16
Net Cash From Continuing Investing Activities
-12 -3.82 -38 -19 -32 -6.79 -5.16
Purchase of Property, Plant & Equipment
-8.77 -3.50 -11 -11 -3.83 -0.76 -0.30
Acquisitions
-3.71 -0.32 -27 -8.02 -28 -6.04 -4.86
Net Cash From Financing Activities
15 18 959 -205 -37 -158 -175
Net Cash From Continuing Financing Activities
15 18 959 -205 -37 -158 -175
Repayment of Debt
-12 -17 -252 0.00 0.00 -156 -411
Repurchase of Preferred Equity
- 0.00 0.00 0.00 -2.24 0.00 0.00
Repurchase of Common Equity
0.00 -0.15 0.00 -160 -30 0.00 0.00
Issuance of Debt
29 37 755 - 0.00 0.00 238
Other Financing Activities, net
-1.77 -0.90 456 -45 -5.05 -1.96 -1.57
Cash Interest Paid
16 14 10 9.82 9.38 8.01 14

Quarterly Cash Flow Statements for Beauty Health

This table details how cash moves in and out of Beauty Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-77 -95 8.02 15 1.60 -165 7.76 13 -28 1.24 -93
Net Cash From Operating Activities
-17 6.20 10 16 3.00 9.65 9.65 15 -5.55 2.67 11
Net Cash From Continuing Operating Activities
-17 6.20 10 16 3.00 9.65 9.65 15 -5.55 -1.04 8.93
Net Income / (Loss) Continuing Operations
-0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63 -2.67 -0.89
Consolidated Net Income / (Loss)
-0.68 0.20 -18 -10 -10 20 -11 -8.10 -6.63 -2.67 -0.89
Depreciation Expense
2.77 2.66 3.06 1.45 1.86 0.71 0.64 0.64 0.56 0.53 0.55
Amortization Expense
6.83 7.05 7.29 5.89 5.09 5.54 8.78 5.72 5.78 5.73 5.71
Non-Cash Adjustments To Reconcile Net Income
-1.85 5.71 18 11 4.14 -9.53 3.77 7.16 3.87 -2.23 0.74
Changes in Operating Assets and Liabilities, net
-24 -9.42 0.16 8.34 2.00 -6.79 7.50 9.78 -9.14 -2.40 2.82
Net Cash From Investing Activities
-1.80 -2.04 -2.09 -0.86 -1.15 -1.55 -1.08 -1.38 -1.65 -1.21 -1.06
Net Cash From Continuing Investing Activities
-1.80 -2.04 -2.09 -0.86 -1.15 -1.55 -1.08 -1.38 -1.65 -1.21 -1.06
Purchase of Property, Plant & Equipment
-0.34 -0.33 -0.00 -0.07 -0.05 -0.09 -0.03 -0.14 -0.22 -0.43 -0.09
Acquisitions
-1.46 -1.70 -2.09 -0.79 -1.10 -1.46 -1.06 -1.24 -1.43 -0.78 -0.97
Net Cash From Financing Activities
-59 -99 -0.20 -0.77 -0.25 -173 -0.80 -0.51 -21 -0.22 -104
Net Cash From Continuing Financing Activities
-59 -99 -0.20 -0.77 -0.25 -173 -0.80 -0.51 -21 -0.22 -104
Repayment of Debt
-58 -98 - -0.30 0.00 -173 -238 - -20 - -83
Other Financing Activities, net
-0.87 -0.42 -0.20 -0.47 -0.25 -0.71 -0.19 -0.43 -0.75 -0.22 -0.27

Annual Balance Sheets for Beauty Health

This table presents Beauty Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
223 1,219 1,003 929 686 500
Total Current Assets
59 1,001 783 698 477 310
Cash & Equivalents
9.49 902 568 523 370 233
Accounts Receivable
19 47 76 55 28 22
Inventories, net
23 35 110 91 69 48
Prepaid Expenses
3.22 12 28 29 9.49 5.40
Current Deferred & Refundable Income Taxes
4.61 4.60 1.28 0.33 0.82 1.70
Plant, Property, & Equipment, net
0.00 16 18 14 5.98 2.54
Total Noncurrent Assets
164 202 202 217 203 188
Goodwill
99 124 125 126 123 127
Intangible Assets
51 56 46 62 48 36
Noncurrent Deferred & Refundable Income Taxes
0.27 0.33 0.82 0.53 3.89 1.93
Other Noncurrent Operating Assets
14 22 30 28 28 23
Total Liabilities & Shareholders' Equity
223 1,219 1,003 929 686 500
Total Liabilities
253 917 836 870 634 439
Total Current Liabilities
31 76 72 115 68 186
Short-Term Debt
0.51 - - - 0.00 124
Accounts Payable
18 29 28 45 22 16
Accrued Expenses
2.46 15 15 20 20 15
Current Deferred & Payable Income Tax Liabilities
0.00 0.29 1.43 2.76 3.43 1.23
Current Employee Benefit Liabilities
9.48 29 22 22 18 25
Other Current Liabilities
0.00 3.71 4.96 26 5.15 5.13
Total Noncurrent Liabilities
222 840 764 755 566 252
Long-Term Debt
216 730 734 738 552 240
Noncurrent Deferred & Payable Income Tax Liabilities
3.99 3.56 2.01 0.70 0.40 0.39
Other Noncurrent Operating Liabilities
1.85 107 28 16 13 12
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-30 302 167 59 52 61
Total Preferred & Common Equity
-30 302 167 59 52 61
Total Common Equity
-30 302 167 59 52 61
Common Stock
14 722 550 541 567 580
Retained Earnings
-44 -419 -379 -479 -508 -517
Accumulated Other Comprehensive Income / (Loss)
0.24 -1.26 -4.53 -3.04 -6.95 -1.43

Quarterly Balance Sheets for Beauty Health

This table presents Beauty Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
845 712 700 674 508 504 473 487 389
Total Current Assets
615 490 485 469 306 308 278 295 202
Cash & Equivalents
445 350 359 373 212 219 204 206 112
Accounts Receivable
48 41 36 23 25 22 19 18 18
Inventories, net
96 77 73 66 59 56 48 47 46
Prepaid Expenses
26 21 16 7.18 7.79 7.43 5.39 23 23
Current Deferred & Refundable Income Taxes
1.20 0.40 0.40 0.27 2.08 3.19 1.64 1.99 1.83
Plant, Property, & Equipment, net
12 9.72 7.63 4.22 3.70 3.05 2.34 2.09 1.85
Total Noncurrent Assets
218 212 207 200 198 192 193 189 186
Goodwill
125 125 125 124 126 126 126 126 126
Intangible Assets
58 54 51 46 43 38 33 30 28
Noncurrent Deferred & Refundable Income Taxes
1.93 3.04 1.17 4.25 3.16 0.99 2.41 2.35 2.16
Other Noncurrent Operating Assets
32 30 29 26 25 27 32 30 30
Total Liabilities & Shareholders' Equity
845 712 700 674 508 504 473 487 389
Total Liabilities
781 643 640 628 434 438 418 431 333
Total Current Liabilities
94 75 74 63 59 62 155 168 70
Short-Term Debt
- - - - - - 103 103 0.00
Accounts Payable
37 27 23 23 23 17 16 16 15
Accrued Expenses
24 24 28 17 14 19 19 32 36
Current Deferred & Payable Income Tax Liabilities
3.44 2.36 1.40 3.31 2.68 1.50 0.46 0.48 0.07
Current Employee Benefit Liabilities
15 17 17 15 15 19 13 13 16
Other Current Liabilities
13 5.19 4.83 5.08 5.17 5.04 4.16 3.86 3.59
Total Noncurrent Liabilities
688 567 566 565 374 376 263 263 263
Long-Term Debt
665 551 551 553 363 363 241 242 243
Noncurrent Deferred & Payable Income Tax Liabilities
1.07 1.06 1.12 0.40 0.22 0.11 0.39 0.39 0.73
Other Noncurrent Operating Liabilities
21 16 13 12 11 13 21 20 20
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
63 69 60 46 74 66 55 56 56
Total Preferred & Common Equity
63 69 60 46 74 66 55 56 56
Total Common Equity
63 69 60 46 74 66 55 56 56
Common Stock
547 553 561 570 575 577 581 584 585
Retained Earnings
-480 -479 -498 -518 -498 -509 -524 -527 -528
Accumulated Other Comprehensive Income / (Loss)
-4.08 -4.90 -3.71 -5.83 -2.20 -1.78 -1.71 -1.40 -1.72

Annual Metrics And Ratios for Beauty Health

This table displays calculated financial ratios and metrics derived from Beauty Health's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 57,500,000.00 149,639,553.00 143,201,041.00 132,885,767.00 - 127,503,059.00
DEI Adjusted Shares Outstanding
0.00 57,500,000.00 149,639,553.00 143,201,041.00 132,885,767.00 - 127,503,059.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.51 -2.53 0.31 -0.75 - -0.07
Growth Metrics
- - - - - - -
Revenue Growth
0.00% -28.53% 118.39% 40.68% 8.78% -16.00% -10.02%
EBITDA Growth
0.00% -104.08% -28,905.85% 122.10% -194.59% 101.68% 2,646.01%
EBIT Growth
0.00% -221.55% -2,043.78% 113.43% -324.82% 67.88% 112.39%
NOPAT Growth
0.00% -227.63% -132.38% 9.82% -263.58% 48.23% 69.31%
Net Income Growth
0.00% -1,681.14% -1,198.25% 111.68% -326.38% 70.94% 67.29%
EPS Growth
0.00% -1,600.00% -336.47% 93.80% -230.43% 52.63% 55.56%
Operating Cash Flow Growth
0.00% -819.68% -128.06% -275.87% 120.40% -25.82% 132.34%
Free Cash Flow Firm Growth
0.00% 0.00% 109.95% -1,311.13% 85.35% 80.10% 500.48%
Invested Capital Growth
0.00% 0.00% -26.41% 155.51% -17.50% -14.85% -17.60%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 5.86% -0.33% -3.83% -0.37%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 27.61% -13.11% -73.20% 46.11%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 50.43% -12.48% 1.00% 162.52%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 10.58% -13.63% 14.19% 26.03%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 161.12% -18.63% -3.29% 18.95%
EPS Q/Q Growth
0.00% 0.00% 0.00% 66.67% -10.14% 16.28% -6.67%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 11.51% -8.86% 1.04% 392.92% -3.29%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -114.76% 97.84% 16.14%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 8.54% 0.00% -7.26% -8.05%
Profitability Metrics
- - - - - - -
Gross Margin
63.92% 56.43% 68.65% 68.00% 38.97% 54.53% 65.28%
EBITDA Margin
17.60% -1.00% -133.38% 20.95% -18.22% 0.36% 11.11%
Operating Margin
8.08% -14.43% -15.35% -7.06% -32.89% -20.27% -6.92%
EBIT Margin
8.50% -14.45% -141.84% 13.54% -27.99% -10.70% 1.47%
Profit (Net Income) Margin
-0.98% -24.50% -145.63% 12.09% -25.16% -8.70% -3.16%
Tax Burden Percent
55.81% 75.81% 99.51% 97.54% 98.26% 98.47% 160.31%
Interest Burden Percent
-20.73% 223.63% 103.18% 91.49% 91.45% 82.58% -133.92%
Effective Tax Rate
0.00% 0.00% 0.00% 2.46% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -13.58% -18.18% -10.88% -30.16% -18.65% -6.83%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -30.15% -2,018.38% -2,315.21% -34.60% -9.42% -3.61%
Return on Net Nonoperating Assets (RNNOA)
0.00% 208.34% -259.97% 29.73% -58.27% -33.68% -10.04%
Return on Equity (ROE)
0.00% 194.76% -278.16% 18.84% -88.42% -52.34% -16.87%
Cash Return on Invested Capital (CROIC)
0.00% -213.58% 12.24% -98.37% -10.99% -2.61% 12.47%
Operating Return on Assets (OROA)
0.00% -7.72% -51.18% 4.46% -11.53% -4.43% 0.75%
Return on Assets (ROA)
0.00% -13.09% -52.55% 3.98% -10.36% -3.60% -1.61%
Return on Common Equity (ROCE)
0.00% 194.79% -278.14% 18.84% -88.42% -52.34% -16.87%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% -56.17% 0.00%
Net Operating Profit after Tax (NOPAT)
9.42 -12 -28 -25 -92 -47 -15
NOPAT Margin
5.66% -10.10% -10.75% -6.89% -23.03% -14.19% -4.84%
Net Nonoperating Expense Percent (NNEP)
0.00% 16.56% 2,000.20% 2,304.33% 4.44% -9.23% -3.21%
Return On Investment Capital (ROIC_SIMPLE)
- -6.45% -2.71% -2.80% -11.49% -7.85% -3.42%
Cost of Revenue to Revenue
36.08% 43.57% 31.35% 32.00% 61.03% 45.47% 34.72%
SG&A Expenses to Revenue
16.00% 25.74% 37.94% 29.00% 33.02% 37.53% 39.21%
R&D to Revenue
2.77% 2.86% 3.15% 2.31% 2.54% 1.88% 1.87%
Operating Expenses to Revenue
55.84% 70.85% 84.00% 75.06% 71.87% 74.81% 72.20%
Earnings before Interest and Taxes (EBIT)
14 -17 -369 50 -111 -36 4.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
29 -1.20 -347 77 -73 1.22 33
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 0.00 11.96 0.00 6.96 3.81 2.90
Price to Tangible Book Value (P/TBV)
0.00 0.00 29.49 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.40 0.00 13.90 0.00 1.04 0.59 0.59
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 26.42 0.00 2.29 1.62 1.60
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 13.24 0.00 1.58 1.14 1.03
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 311.82 9.24
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 69.68
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 28.90 23.52 8.24
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 183.01 0.00 0.00 0.00 11.61
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 -7.23 2.41 4.39 12.43 10.66 5.97
Long-Term Debt to Equity
0.00 -7.21 2.41 4.39 12.43 10.66 3.94
Financial Leverage
0.00 -6.91 0.13 -0.01 1.68 3.57 2.78
Leverage Ratio
0.00 -7.44 5.29 4.73 8.53 14.52 10.50
Compound Leverage Factor
0.00 -16.63 5.46 4.33 7.80 11.99 -14.07
Debt to Total Capital
0.00% 116.06% 70.71% 81.46% 92.56% 91.42% 85.65%
Short-Term Debt to Total Capital
0.00% 0.27% 0.00% 0.00% 0.00% 0.00% 29.14%
Long-Term Debt to Total Capital
0.00% 115.78% 70.71% 81.46% 92.56% 91.42% 56.51%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -16.06% 29.28% 18.54% 7.44% 8.58% 14.35%
Debt to EBITDA
0.00 -181.05 -2.10 9.58 -10.18 453.74 10.90
Net Debt to EBITDA
0.00 -173.12 0.50 2.16 -2.97 149.66 3.94
Long-Term Debt to EBITDA
0.00 -180.62 -2.10 9.58 -10.18 453.74 7.19
Debt to NOPAT
0.00 -18.00 -26.12 -29.13 -8.06 -11.64 -25.02
Net Debt to NOPAT
0.00 -17.21 6.15 -6.58 -2.35 -3.84 -9.05
Long-Term Debt to NOPAT
0.00 -17.96 -26.12 -29.13 -8.06 -11.64 -16.51
Altman Z-Score
0.00 0.00 2.01 0.00 0.35 0.18 -0.28
Noncontrolling Interest Sharing Ratio
0.00% -0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.00 1.91 13.09 10.92 6.07 7.00 1.66
Quick Ratio
0.00 0.91 12.41 8.99 5.02 5.84 1.37
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -189 19 -228 -33 -6.64 27
Operating Cash Flow to CapEx
19.69% -355.21% -253.20% -982.76% 568.63% 2,134.13% 12,371.29%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 1.60 -17.02 -2.45 -0.64 1.38
Operating Cash Flow to Interest Expense
0.00 0.00 -2.41 -7.96 1.59 1.55 1.94
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -3.36 -8.77 1.31 1.48 1.92
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.53 0.36 0.33 0.41 0.41 0.51
Accounts Receivable Turnover
0.00 6.41 7.95 5.93 6.07 8.12 12.18
Inventory Turnover
0.00 2.24 2.79 1.62 2.42 1.89 1.78
Fixed Asset Turnover
0.00 0.00 0.00 21.29 24.56 33.09 70.64
Accounts Payable Turnover
0.00 2.81 3.43 4.07 6.63 4.56 5.56
Days Sales Outstanding (DSO)
0.00 56.93 45.89 61.51 60.16 44.95 29.96
Days Inventory Outstanding (DIO)
0.00 163.20 130.84 225.86 151.02 192.63 204.69
Days Payable Outstanding (DPO)
0.00 130.02 106.38 89.64 55.03 80.10 65.66
Cash Conversion Cycle (CCC)
0.00 90.11 70.35 197.73 156.14 157.48 168.99
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 177 130 333 275 234 193
Invested Capital Turnover
0.00 1.35 1.69 1.58 1.31 1.31 1.41
Increase / (Decrease) in Invested Capital
0.00 177 -47 203 -58 -41 -41
Enterprise Value (EV)
0.00 0.00 3,443 0.00 629 379 309
Market Capitalization
400 0.00 3,615 0.00 413 197 177
Book Value per Share
$0.00 ($0.52) $2.02 $1.13 $0.45 $0.42 $0.48
Tangible Book Value per Share
$0.00 ($3.12) $0.82 ($0.03) ($0.97) ($0.96) ($0.79)
Total Capital
0.00 187 1,032 901 798 604 425
Total Debt
0.00 217 730 734 738 552 364
Total Long-Term Debt
0.00 216 730 734 738 552 240
Net Debt
0.00 207 -172 166 215 182 132
Capital Expenditures (CapEx)
8.77 3.50 11 11 3.83 0.76 0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 19 23 143 60 39 15
Debt-free Net Working Capital (DFNWC)
0.00 29 924 712 583 409 247
Net Working Capital (NWC)
0.00 28 924 712 583 409 123
Net Nonoperating Expense (NNE)
11 17 351 -69 8.47 -18 -5.04
Net Nonoperating Obligations (NNO)
0.00 207 -172 166 215 182 132
Total Depreciation and Amortization (D&A)
15 16 22 27 39 37 29
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 16.11% 8.68% 39.18% 15.13% 11.64% 4.83%
Debt-free Net Working Capital to Revenue
0.00% 24.08% 355.44% 194.48% 146.55% 122.34% 82.18%
Net Working Capital to Revenue
0.00% 23.65% 355.44% 194.48% 146.55% 122.34% 40.97%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.09) ($3.67) $0.30 ($0.76) ($0.23) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding
0.00 57.50M 102.11M 147.55M 131.68M 123.83M 126.38M
Adjusted Diluted Earnings per Share
$0.00 ($0.09) ($3.67) ($0.23) ($0.76) ($0.36) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 57.50M 102.11M 148.51M 131.68M 142.49M 135.80M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($0.09) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 56.10M 150.60M 132.50M 123.43M 125.25M 127.77M
Normalized Net Operating Profit after Tax (NOPAT)
9.42 -12 -28 -25 -92 -47 -15
Normalized NOPAT Margin
5.66% -10.10% -10.75% -6.89% -23.03% -14.19% -4.84%
Pre Tax Income Margin
-1.76% -32.31% -146.35% 12.39% -25.60% -8.84% -1.97%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
0.00 0.00 -31.32 3.70 -8.16 -3.44 0.23
NOPAT to Interest Expense
0.00 0.00 -2.37 -1.88 -6.71 -4.56 -0.75
EBIT Less CapEx to Interest Expense
0.00 0.00 -32.27 2.89 -8.44 -3.51 0.21
NOPAT Less CapEx to Interest Expense
0.00 0.00 -3.32 -2.69 -6.99 -4.63 -0.77
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% -1.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -1.64% 0.00% 361.79% -30.12% 0.00% 0.00%

Quarterly Metrics And Ratios for Beauty Health

This table displays calculated financial ratios and metrics derived from Beauty Health's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
123,427,416.00 123,632,222.00 124,020,249.00 - 125,245,176.00 125,994,343.00 126,825,397.00 127,503,059.00 127,773,050.00 129,600,040.00 130,140,763.00
DEI Adjusted Shares Outstanding
123,427,416.00 123,632,222.00 124,020,249.00 - 125,245,176.00 125,994,343.00 126,825,397.00 127,503,059.00 127,773,050.00 129,600,040.00 6,507,038.00
DEI Earnings Per Adjusted Shares Outstanding
-0.01 0.00 -0.15 - -0.08 0.16 -0.09 -0.06 -0.05 -0.02 -0.14
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-5.65% -22.88% -19.11% -13.76% -14.52% -13.70% -10.34% -1.35% -6.71% -7.77% -2.10%
EBITDA Growth
133.90% -24.81% 86.98% -413.95% -146.92% 232.01% 145.48% 255.54% 257.79% -62.23% 188.34%
EBIT Growth
85.23% -69.47% 74.54% 3.04% -165.59% 1,140.94% 70.19% 100.46% 79.94% -82.01% 185.31%
NOPAT Growth
1.84% 59.02% 73.79% 61.02% 29.24% 81.63% 70.99% 102.26% 85.02% 187.94% 179.75%
Net Income Growth
96.65% -94.00% 75.22% -9.86% -1,386.89% 9,658.42% 39.69% 21.55% 34.33% -113.54% 91.95%
EPS Growth
33.33% -433.33% 73.21% 87.50% 20.00% 130.00% 40.00% -100.00% 37.50% -166.67% 91.95%
Operating Cash Flow Growth
-29.55% -71.77% -42.58% 418.61% 117.78% 55.56% -6.48% -7.75% -285.38% -72.31% 16.75%
Free Cash Flow Firm Growth
136.54% 151.02% -207.21% -21.19% -8.85% -32.41% 114.30% 15.34% -40.36% -22.28% -29.88%
Invested Capital Growth
-18.95% -22.42% 0.00% -14.85% -20.46% -16.71% -16.89% -17.60% -13.68% -13.50% -11.12%
Revenue Q/Q Growth
-15.92% 11.29% -13.02% 5.96% -16.67% 12.37% -9.63% 16.58% -21.20% 11.10% -4.08%
EBITDA Q/Q Growth
838.98% 31.77% -207.55% 50.92% 32.54% 1,032.47% -85.27% 67.86% -31.56% 123.20% 12.45%
EBIT Q/Q Growth
69.03% 48.35% -890.54% 38.81% 15.16% 302.43% -128.37% 100.95% -3,784.91% 281.46% 34.57%
NOPAT Q/Q Growth
7.46% -30.13% 2.70% 66.73% -67.99% 66.22% -53.68% 102.60% -1,211.73% 298.33% 39.36%
Net Income Q/Q Growth
92.78% 129.75% -9,154.95% 43.52% 2.27% 295.25% -155.96% 26.53% 18.19% 59.74% 66.73%
EPS Q/Q Growth
-25.00% 0.00% -50.00% 93.33% -700.00% 137.50% -400.00% 77.78% -150.00% 60.00% 66.73%
Operating Cash Flow Q/Q Growth
-226.00% 136.79% 66.34% 59.69% -81.81% 221.96% 0.01% 57.52% -136.55% 148.09% 321.68%
Free Cash Flow Firm Q/Q Growth
20.11% 14.82% -526.84% 113.39% 38.91% -14.86% -9.70% 7.99% -28.17% 10.94% -18.53%
Invested Capital Q/Q Growth
3.43% -4.88% -6.67% -7.26% -3.39% -0.41% -6.86% -8.05% 1.21% -0.20% -4.30%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
59.41% 45.19% 51.58% 62.69% 69.82% 62.81% 64.59% 64.39% 68.46% 68.42% 68.16%
EBITDA Margin
7.29% 8.63% -10.67% -4.94% -4.00% 33.20% 5.41% 7.79% 6.77% 13.60% 15.94%
Operating Margin
-20.87% -24.41% -27.30% -8.57% -17.28% -3.45% -8.83% 0.20% -2.77% 4.95% 7.20%
EBIT Margin
-4.50% -2.09% -23.80% -13.74% -13.99% 25.20% -7.91% 0.06% -3.01% 4.91% 6.89%
Profit (Net Income) Margin
-0.83% 0.22% -23.21% -12.37% -14.51% 25.21% -15.61% -9.84% -10.21% -3.70% -1.28%
Tax Burden Percent
50.75% -133.77% 111.92% 88.16% 109.69% 105.30% 103.63% 168.55% 97.30% 182.68% 822.22%
Interest Burden Percent
36.51% 7.98% 87.16% 102.14% 94.56% 95.00% 190.43% -9,071.70% 348.90% -41.22% -2.26%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% -5.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-18.10% -20.23% -52.68% -7.89% -15.29% -4.55% -8.08% 0.19% -2.73% 4.79% 7.34%
ROIC Less NNEP Spread (ROIC-NNEP)
-12.81% -12.14% -56.03% -10.56% -16.13% 8.26% -12.04% -5.04% -6.09% 1.23% 4.16%
Return on Net Nonoperating Assets (RNNOA)
-25.72% -20.36% -180.62% -37.76% -59.12% 20.31% -32.32% -14.02% -19.22% 2.75% 9.40%
Return on Equity (ROE)
-43.82% -40.59% -233.30% -45.65% -74.41% 15.76% -40.41% -13.83% -21.96% 7.54% 16.74%
Cash Return on Invested Capital (CROIC)
-7.87% -6.33% -243.83% -2.61% 5.55% 5.97% 9.92% 12.47% 11.16% 13.04% 14.22%
Operating Return on Assets (OROA)
-1.92% -0.89% -11.82% -5.69% -5.94% 12.82% -3.97% 0.03% -1.55% 2.87% 4.46%
Return on Assets (ROA)
-0.36% 0.10% -11.53% -5.12% -6.16% 12.82% -7.84% -4.99% -5.27% -2.16% -0.83%
Return on Common Equity (ROCE)
-43.82% -40.59% -233.30% -45.65% -74.41% 15.76% -40.41% -13.83% -21.96% 7.54% 16.74%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-12 -15 -15 -5.01 -8.42 -2.84 -4.37 0.11 -1.26 2.50 3.48
NOPAT Margin
-14.61% -17.08% -19.11% -6.00% -12.10% -3.64% -6.18% 0.14% -1.94% 3.47% 5.04%
Net Nonoperating Expense Percent (NNEP)
-5.29% -8.09% 3.36% 2.68% 0.84% -12.81% 3.96% 5.24% 3.36% 3.56% 3.19%
Return On Investment Capital (ROIC_SIMPLE)
-1.63% -2.50% -2.46% -0.83% -1.40% -0.65% -1.02% 0.03% -0.32% 0.62% 1.17%
Cost of Revenue to Revenue
40.59% 54.81% 48.42% 37.31% 30.18% 37.19% 35.41% 35.61% 31.54% 31.58% 31.84%
SG&A Expenses to Revenue
35.45% 34.67% 42.43% 38.03% 48.24% 35.11% 41.40% 33.61% 33.81% 32.37% 29.64%
R&D to Revenue
3.45% 1.28% 1.41% 1.46% 1.43% 1.60% 2.40% 2.04% 1.70% 1.95% 2.40%
Operating Expenses to Revenue
80.28% 69.60% 78.89% 71.27% 87.10% 66.27% 73.42% 64.19% 71.24% 63.46% 60.96%
Earnings before Interest and Taxes (EBIT)
-3.67 -1.89 -19 -11 -9.73 20 -5.59 0.05 -1.95 3.54 4.77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
5.93 7.82 -8.41 -4.13 -2.78 26 3.82 6.42 4.39 9.81 11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
8.66 3.43 2.99 3.81 3.64 3.25 3.84 2.90 2.06 1.62 1.47
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.39 0.65 0.51 0.59 0.52 0.78 0.84 0.59 0.38 0.31 0.28
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.71 1.62 1.47 1.62 1.54 1.74 1.89 1.60 1.30 1.18 1.14
Enterprise Value to Revenue (EV/Rev)
1.96 1.20 1.07 1.14 1.08 1.26 1.31 1.03 0.86 0.79 0.74
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 81.72 311.82 0.00 36.82 17.33 9.24 6.25 9.36 6.72
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.68 20.76 0.00 33.15
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.94
Enterprise Value to Operating Cash Flow (EV/OCF)
42.94 204.79 0.00 23.52 9.66 9.94 10.23 8.24 8.76 10.42 9.02
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 24.55 26.48 17.30 11.61 10.79 8.36 7.55
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
10.51 7.96 9.23 10.66 12.01 4.91 5.53 5.97 6.23 6.21 4.36
Long-Term Debt to Equity
10.51 7.96 9.23 10.66 12.01 4.91 5.53 3.94 4.37 4.36 4.36
Financial Leverage
2.01 1.68 3.22 3.57 3.67 2.46 2.68 2.78 3.16 2.24 2.26
Leverage Ratio
8.72 7.44 11.71 14.52 13.89 8.52 9.60 10.50 11.32 7.67 7.35
Compound Leverage Factor
3.18 0.59 10.21 14.83 13.13 8.09 18.27 -952.90 39.51 -3.16 -0.17
Debt to Total Capital
91.31% 88.84% 90.23% 91.42% 92.31% 83.07% 84.70% 85.65% 86.17% 86.13% 81.34%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.14% 25.77% 25.72% 0.00%
Long-Term Debt to Total Capital
91.31% 88.84% 90.23% 91.42% 92.31% 83.07% 84.70% 56.51% 60.40% 60.41% 81.34%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
8.69% 11.16% 9.77% 8.58% 7.69% 16.93% 15.30% 14.35% 13.83% 13.87% 18.67%
Debt to EBITDA
-13.56 -10.66 121.43 453.74 -73.72 34.13 15.89 10.90 8.48 14.12 7.68
Net Debt to EBITDA
-4.50 -3.89 42.40 149.66 -23.99 14.20 6.30 3.94 3.45 5.69 4.13
Long-Term Debt to EBITDA
-13.56 -10.66 121.43 453.74 -73.72 34.13 15.89 7.19 5.94 9.91 7.68
Debt to NOPAT
-7.28 -5.64 -9.97 -11.64 -12.58 -11.95 -18.46 -25.02 -46.47 -114.45 50.22
Net Debt to NOPAT
-2.42 -2.06 -3.48 -3.84 -4.09 -4.97 -7.31 -9.05 -18.88 -46.13 26.99
Long-Term Debt to NOPAT
-7.28 -5.64 -9.97 -11.64 -12.58 -11.95 -18.46 -16.51 -32.58 -80.27 50.22
Altman Z-Score
0.82 0.48 0.29 0.30 0.24 0.28 0.08 -0.31 -0.46 -0.46 -0.56
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.57 6.49 6.56 7.00 7.47 5.15 4.98 1.66 1.79 1.76 2.89
Quick Ratio
5.26 5.18 5.34 5.84 6.31 3.99 3.90 1.37 1.44 1.33 1.87
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
55 63 -267 36 50 42 38 41 30 33 27
Operating Cash Flow to CapEx
-4,899.42% 1,856.59% 257,875.00% 22,259.46% 6,657.78% 10,484.78% 35,729.63% 10,932.37% -2,479.46% 625.53% 12,110.75%
Free Cash Flow to Firm to Interest Expense
18.01 25.54 -108.31 14.53 19.90 10.21 6.06 6.48 4.67 5.23 4.27
Operating Cash Flow to Interest Expense
-5.56 2.53 4.18 6.69 1.20 2.33 1.53 2.38 -0.88 0.42 1.80
Operating Cash Flow Less CapEx to Interest Expense
-5.68 2.39 4.18 6.66 1.18 2.31 1.52 2.36 -0.91 0.36 1.78
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.43 0.43 0.50 0.41 0.42 0.51 0.50 0.51 0.52 0.58 0.65
Accounts Receivable Turnover
6.64 6.31 9.58 8.12 9.09 9.33 10.32 12.18 14.14 13.59 14.19
Inventory Turnover
2.24 2.65 2.34 1.89 1.73 1.75 1.64 1.78 1.83 1.84 1.85
Fixed Asset Turnover
25.86 26.47 45.54 33.09 39.64 46.20 56.50 70.64 90.34 100.15 117.66
Accounts Payable Turnover
6.80 8.70 7.45 4.56 4.63 4.81 5.26 5.56 5.32 5.00 5.84
Days Sales Outstanding (DSO)
54.99 57.83 38.09 44.95 40.14 39.11 35.35 29.96 25.81 26.86 25.73
Days Inventory Outstanding (DIO)
163.07 137.84 155.87 192.63 210.40 208.42 222.60 204.69 199.06 198.27 197.53
Days Payable Outstanding (DPO)
53.64 41.97 48.99 80.10 78.83 75.92 69.36 65.66 68.55 72.98 62.47
Cash Conversion Cycle (CCC)
164.43 153.70 144.97 157.48 171.71 171.61 188.59 168.99 156.31 152.15 160.79
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
284 270 252 234 226 225 210 193 195 195 186
Invested Capital Turnover
1.24 1.18 2.76 1.31 1.26 1.25 1.31 1.41 1.41 1.38 1.46
Increase / (Decrease) in Invested Capital
-66 -78 252 -41 -58 -45 -43 -41 -31 -30 -23
Enterprise Value (EV)
769 438 371 379 348 392 396 309 254 229 213
Market Capitalization
548 237 179 197 168 241 252 177 114 90 82
Book Value per Share
$0.51 $0.56 $0.48 $0.42 $0.37 $0.59 $0.52 $0.48 $0.43 $0.43 $0.43
Tangible Book Value per Share
($0.98) ($0.89) ($0.94) ($0.96) ($0.99) ($0.76) ($0.78) ($0.79) ($0.81) ($0.78) ($0.75)
Total Capital
729 620 611 604 599 437 429 425 399 401 299
Total Debt
665 551 551 552 553 363 363 364 344 345 243
Total Long-Term Debt
665 551 551 552 553 363 363 240 241 242 243
Net Debt
221 201 193 182 180 151 144 132 140 139 131
Capital Expenditures (CapEx)
0.34 0.33 0.00 0.07 0.05 0.09 0.03 0.14 0.22 0.43 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)
77 65 52 39 34 35 27 15 21 24 19
Debt-free Net Working Capital (DFNWC)
521 414 411 409 407 247 246 247 225 230 132
Net Working Capital (NWC)
521 414 411 409 407 247 246 123 122 127 132
Net Nonoperating Expense (NNE)
-11 -16 3.23 5.32 1.68 -23 6.66 8.22 5.37 5.17 4.37
Net Nonoperating Obligations (NNO)
221 201 193 182 180 151 144 132 140 139 131
Total Depreciation and Amortization (D&A)
9.60 9.71 10 7.35 6.95 6.26 9.41 6.37 6.35 6.26 6.26
Debt-free, Cash-free Net Working Capital to Revenue
19.49% 17.65% 15.02% 11.64% 10.40% 11.18% 8.96% 4.83% 7.12% 8.29% 6.71%
Debt-free Net Working Capital to Revenue
132.60% 113.10% 118.26% 122.34% 126.08% 79.55% 81.63% 82.18% 76.13% 79.34% 45.66%
Net Working Capital to Revenue
132.60% 113.10% 118.26% 122.34% 126.08% 79.55% 81.63% 40.97% 41.37% 43.80% 45.66%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.01) $0.00 ($0.15) ($0.07) ($0.08) $0.16 ($0.09) ($0.07) ($0.05) ($0.02) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding
123.12M 123.72M 124.06M 123.83M 125.08M 126.07M 126.89M 126.38M 127.79M 129.60M 6.51M
Adjusted Diluted Earnings per Share
($0.10) ($0.10) ($0.15) ($0.01) ($0.08) $0.03 ($0.09) ($0.02) ($0.05) ($0.02) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding
144.48M 141.93M 124.06M 142.49M 125.08M 140.29M 126.89M 135.80M 131.40M 129.60M 6.51M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
123.63M 124.02M 124.12M 125.25M 125.99M 126.83M 127.50M 127.77M 129.60M 130.14M 6.54M
Normalized Net Operating Profit after Tax (NOPAT)
-12 -15 -15 -5.01 -8.42 -1.89 -4.37 0.11 -1.26 2.50 3.48
Normalized NOPAT Margin
-14.61% -17.08% -19.11% -6.00% -12.10% -2.42% -6.18% 0.14% -1.94% 3.47% 5.04%
Pre Tax Income Margin
-1.64% -0.17% -20.74% -14.03% -13.23% 23.94% -15.07% -5.84% -10.50% -2.03% -0.16%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-1.21 -0.77 -7.60 -4.66 -3.90 4.76 -0.89 0.01 -0.31 0.56 0.76
NOPAT to Interest Expense
-3.93 -6.31 -6.10 -2.03 -3.37 -0.69 -0.69 0.02 -0.20 0.40 0.56
EBIT Less CapEx to Interest Expense
-1.32 -0.91 -7.60 -4.69 -3.91 4.73 -0.89 -0.01 -0.34 0.50 0.75
NOPAT Less CapEx to Interest Expense
-4.04 -6.45 -6.10 -2.06 -3.39 -0.71 -0.70 0.00 -0.23 0.33 0.54
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Beauty Health’s recent results show a mixed but improving operating profile. Revenue has declined over the period, but gross margins and operating income have improved substantially. The company remains unprofitable, carries significant debt and has a large accumulated retained-earnings deficit.

  • Operating profitability improved sharply. Q2 2026 operating income was $3.6 million, compared with operating losses of $1.8 million in Q1 2026, $2.7 million in Q2 2025 and $22.1 million in Q2 2024.
  • Gross margin expanded. Q2 2026 gross profit was $49.3 million on $72.1 million of revenue, producing an approximately 68.4% gross margin. That compares with 62.8% in Q2 2025 and 45.2% in Q2 2024.
  • Quarterly revenue rebounded sequentially. Revenue increased 11.1% from $64.9 million in Q1 2026 to $72.1 million in Q2. SG&A and marketing expenses also declined sequentially, helping the company reach positive operating income.
  • Net losses narrowed in 2026. Q2 2026 net loss was $2.7 million, an improvement from the $6.6 million loss in Q1 2026 and the $11.0 million loss in Q3 2025.
  • Debt has declined materially. Total debt was approximately $345.2 million at June 30, 2026, down from roughly $914.8 million at March 31, 2024. The company made substantial debt repayments during 2024 and 2025.
  • Liquidity remains adequate in the near term. Beauty Health held $206.1 million in cash and equivalents at the end of Q2 2026, while current assets of $295.2 million exceeded current liabilities of $168.2 million.
  • Cash flow performance is uneven. Reported net cash from operating activities was positive at $2.7 million in Q2 2026 after a $5.6 million outflow in Q1. However, continuing operating activities were reported as a $1.0 million outflow, indicating that investors should review the underlying cash-flow reconciliation.
  • Cash has stabilized but remains well below prior levels. Cash declined from $444.6 million in Q1 2024 to $206.1 million in Q2 2026. It has been relatively stable around $200 million during 2025 and 2026, but the company has less financial flexibility than it did two years ago.
  • Revenue remains in a multiyear downtrend. Q2 revenue fell from $90.6 million in 2024 to $78.2 million in 2025 and $72.1 million in 2026, a decline of approximately 20% over two years. Q2 2026 revenue was still below the $82.4 million reported in Q4 2025.
  • The company continues to report net losses and has a large retained deficit. Q2 2026 net loss was $2.7 million, and retained earnings were negative $526.8 million. Interest expense of $6.3 million also exceeded interest and investment income of $1.3 million during the quarter.

Overall, the statements indicate that Beauty Health is making progress on gross margins, cost control, operating profitability and debt reduction. However, the improvement has not yet translated into consistent net profitability or sustained revenue growth. Investors should closely monitor whether the recent operating-income improvement continues, whether operating cash flow turns consistently positive and whether revenue can return to growth.

11/19/26 06:05 AM ETAI Generated. May Contain Errors.

Beauty Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Beauty Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Beauty Health's net income appears to be on an upward trend, with a most recent value of -$9.52 million in 2025, falling from -$1.64 million in 2019. The previous period was -$29.10 million in 2024. See Beauty Health's forecast for analyst expectations on what's next for the company.

Beauty Health's total operating income in 2025 was -$20.80 million, based on the following breakdown:
  • Total Gross Profit: $196.36 million
  • Total Operating Expenses: $217.17 million

Over the last 6 years, Beauty Health's total revenue changed from $166.62 million in 2019 to $300.79 million in 2025, a change of 80.5%.

In the past 10 quarters, Beauty Health's cash and equivalents has ranged from $112.39 million in Q3 2026 to $444.63 million in Q1 2024, and is currently $112.39 million as of their latest financial filing in Q3 2026.

Beauty Health had total debt of $364.39 million at the end of 2025, a 34.0% decrease from 2024, and none in 2019.

Over the last 6 years, Beauty Health's book value per share changed from 0.00 in 2019 to 0.48 in 2025, a change of 47.9%.



Financial statements for NASDAQ:SKIN last updated on 11/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners